Matthew W. McCarthy
A5059612543- Antifungal resistance and susceptibility
- COVID-19 Clinical Research Studies
- Fungal Infections and Studies
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Pharmacological Receptor Mechanisms and Effects
- Antimicrobial Resistance in Staphylococcus
- Antibiotic Resistance in Bacteria
- Sepsis Diagnosis and Treatment
- Bacterial Identification and Susceptibility Testing
- Infectious Diseases and Mycology
- Antibiotics Pharmacokinetics and Efficacy
- Parasitic Diseases Research and Treatment
- Antibiotic Use and Resistance
- Plant Pathogens and Fungal Diseases
- Nail Diseases and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 and Mental Health
- Urinary Tract Infections Management
- Epilepsy research and treatment
- COVID-19 and healthcare impacts
- Ethics in medical practice
- Ethics in Clinical Research
- Healthcare cost, quality, practices
- Nosocomial Infections in ICU
Weill Cornell Medicine
2017-2025
Cornell University
2016-2025
New York Hospital Queens
2016-2024
NewYork–Presbyterian Hospital
2016-2024
Presbyterian Hospital
2016-2022
Institute of Accelerating Systems and Applications
2022
Rancho Santa Ana Botanic Garden
2021
Hospital for Special Surgery
2019-2020
General Department of Preventive Medicine
2017
Royal Perth Hospital
2001
The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild moderate symptomatic COVID-19 is unknown.To evaluate efficacy ivermectin, 400 μg/kg, daily for 3 days compared placebo treatment early COVID-19.ACTIV-6, an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial, was designed repurposed therapies COVID-19. A total 1591 participants aged 30 years and older confirmed COVID-19, experiencing 2...
Importance The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild moderate symptomatic COVID-19 is unclear. Objective To evaluate the efficacy low-dose (50 mg twice daily) for 10 days compared placebo treatment in US. Design, Setting, and Participants ongoing Accelerating Therapeutic Interventions Vaccines (ACTIV-6) platform randomized clinical trial was designed test repurposed medications COVID-19. A total 1288 participants aged...
It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients mild to moderate COVID-19.
Importance Immune dysregulation contributes to poorer outcomes in COVID-19. Objective To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added standard care for COVID-19 pneumonia. Design, Setting, and Participants Randomized, double-masked, placebo-controlled clinical trial using a master protocol immunomodulators treatment of participants hospitalized with The results 3 substudies are reported from 95 hospitals at 85 research sites the US Latin America....
Biofilm formation by Candida albicans poses an important therapeutic challenge in human diseases. Typically, conventional antifungal agents encounter difficulty treating and fully eradicating biofilm-related infections. Novel approaches are needed to treat recalcitrant biofilms. Farnesol is a quorum-sensing molecule, which induces apoptosis, inhibits Ras protein pathways profoundly affects the morphogenesis of C. albicans. We therefore investigated interactions between farnesol different...
Monkeypox is a viral zoonosis, with symptoms similar to those seen in smallpox patients, although the clinical presentation may be less severe. Until recently, human monkeypox infection was rare, and primarily occurred Central West Africa.An international outbreak began May 2022, has now been detected on every continent except Antarctica. The first recognized case from current confirmed United Kingdom 6 an adult travel links Nigeria, but it suggested that cases had spreading Europe for...
The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain.
Introduction Monkeypox virus is a zoonotic double-stranded DNA poxvirus in the genus Orthopoxvirus, family Poxviridae. Until recently, monkeypox was found primarily Central and West Africa, where had split into Congo Basin African clades.Areas Covered On 6 May 2022, detected United Kingdom has now been every continent except Antarctica. The current outbreak represents first documentation of widespread community transmission outside Africa.Expert Opinion 23 July World Health Organization...
The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear.
On 31 July 2023, the United States Department of Health and Human Services announced formation Office Long COVID Research Practice National Institutes opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options long Coronavirus (long COVID).The RECOVER Initiative is $1.15 billion research platform intended describe, categorize, treat, prevent long-term symptoms following infection by Severe Acute Respiratory Syndrome 2 (SARS‑CoV‑2), virus that causes (COVID-19)....
Importance: The effect of metformin on reducing symptom duration among outpatient adults with coronavirus disease 2019 (COVID-19) has not been studied. Objective: Assess compared placebo for resolution during acute infection SARS-CoV-2. Design, Setting, and Participants: ACTIV-6 platform evaluated repurposed medications mild to moderate COVID-19. Between September 19, 2023, May 1, 2024, 2991 participants age >=30 years confirmed SARS-CoV-2 >=2 COVID-19 symptoms <=7 days, were...
Introduction On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection treatment of adults with acute bacterial skin structure infections (ABSSSI) as well patients Staphylococcus aureus bloodstream three months to less than 18 years old community-acquired pneumonia.
Whether isavuconazole, an extended-spectrum triazole, possesses synergistic activity in combination therapy with echinocandins or amphotericin B for the treatment of invasive molds infections has not been studied. Our vitro studies showed that isavuconazole and micafungin are synergistically active against Aspergillus fumigatus, flavus, terreus, Cunninghamella bertholletiae. These results suggest micafungin, may have a role aspergillosis warrants further investigation.
Admissions for acute bacterial skin and structure infections (ABSSSI) are often prolonged because of intravenous (IV) antibiotics. Use a long-acting IV antibiotic may reduce length stay (LOS) on hospitalist service. The ENHANCE ABSSSI trial sought to determine the impact LOS work productivity in patients treated with antibiotic, dalbavancin, vs. usual care at an urban tertiary-care center. A single-center, pre- post-period pragmatic Weill-Cornell Medical Center assessed consecutively...